New chemo drug shows promise for kids with blood cancer

NCT ID NCT01574274

First seen Feb 05, 2026 · Last updated Apr 30, 2026 · Updated 13 times

Summary

This study tests a new form of chemotherapy called calaspargase pegol (SC-PEG) in 240 children and teens with acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if giving it every 3 weeks is as safe and effective as the standard drug Oncaspar given every 2 weeks. The study also looks at whether adjusting treatment based on early cancer levels and giving preventive antibiotics can improve outcomes and reduce infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Hospitalier U. de Quebec

    Québec, Quebec, Canada

  • Children's Hospital Boston

    Boston, Massachusetts, 02215, United States

  • Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hasbro Children's Hospital

    Providence, Rhode Island, 02903, United States

  • Hospital Sainte Justine, University of Montreal

    Montreal, Quebec, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • Montefiore Medical Center

    New York, New York, 10467, United States

Conditions

Explore the condition pages connected to this study.